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ABSTRACT
Introduction. International guidelines differ regarding
their recommendations on axillary treatment of patients
with non-visualized sentinel lymph nodes (non-vSLN).
Therefore, we distributed a survey among Dutch oncolog-
ical surgeons to determine their routine practice and
opinion regarding axillary treatment in case of a non-
vSLN, with the emphasis on whether these practices and
opinions have changed since publication of the Z0011 trial.
Methods. A Dutch nationwide survey containing 10
questions regarding clinical routine during the sentinel
node procedure and axillary treatment of non-vSLN
patients was distributed among 510 oncological surgeons.
Results. The survey was completed by 122 (24%) onco-
logical surgeons, of whom 116 (95%) were registered as
specialized breast surgeons. These surgeons had, on aver-
age, 13 years of experience. The majority of respondents
used both lymphoscintigraphy and Patent Blue during the
sentinel node procedure, and 39% estimated the prevalence
of a non-vSLN to be 1–2%. Most surgeons are currently
more reserved when considering whether to perform an
axillary lymph node dissection (ALND) than prior to
publication of the Z0011 trial (15 vs. 80%, respectively).
Sixty percent base their decision on various clinicopatho-
logical characteristics. Twenty-three respondents (20%)
opted for an alternative axillary treatment.
Conclusion. This study shows that, in daily practice, most
specialized breast surgeons think that a non-vSLN is rare.
If so, most currently opt not to perform an ALND, whereas
a small proportion consider an alternative axillary treat-
ment. These decisions differ than in the period prior to the
Z0011 trial. More research is needed to provide optimal
treatment recommendations in case of a non-vSLN.
Since its introduction in the 1990s, the sentinel lymph
node (SLN) procedure has become a standard element in
the axillary work-up. Prior to introduction of the SLN
procedure, every patient with invasive breast cancer
underwent an axillary lymph node dissection (ALND). The
SLN procedure has made it possible to select patients
without axillary metastases, in whom the ALND could then
be omitted. More recently, studies such as the Z0011 trial
also showed that the ALND could be omitted in selected
SLN-positive patients.1–4 However, in 2–4% of SLN pro-
cedures, the sentinel node cannot be visualized and
retrieved (non-vSLN), after which an ALND should still be
performed according to the current Dutch guideline.5–7
Scientific studies are scarce and international guidelines
differ in their recommendations on whether or not an
ALND should be performed in case of a non-vSLN.6,8–10
The lack of scientific evidence may lead to different axil-
lary treatment regimens between hospitals and surgeons.
Therefore, we distributed a survey among certified onco-
logical surgeons in The Netherlands in order to gain some
Electronic supplementary material The online version of this
article (doi:10.1245/s10434-017-5824-4) contains supplementary
material, which is available to authorized users.
 The Author(s) 2017. This article is published with open access
at Springerlink.com
First Received: 13 December 2016




insight into their routines during the SLN procedure, and to
gauge respondents’ opinions regarding axillary treatment
options in case of a non-vSLN. Do they perform an
immediate ALND in all patients with non-vSLN or do they
differentiate between patients based on indicative factors?
Did they change their routine practice after publication of
the Z0011 trial?
METHODS
The survey was developed by the authors and dis-
tributed, through mail, among certified surgeons registered
with the Dutch Association of Surgical Oncologists
(NVCO), a subdivision of the Dutch Association of Sur-
gery (NVVH). The survey was distributed among 510
oncological surgeons, of whom 116 were registered as
specialized breast cancer surgeons. Because publication of
the Z0011 trial caused a paradigm shift in the axillary
management of node-positive patients, questions were
designed to assess practice patterns both before and after
publication of the Z0011 trial. The final question of the
survey was to gauge the respondents’ perceptions on the
current Dutch guideline regarding the axillary management
of patients with a non-vSLN (see Supplementary Material
Appendix 1 for the complete survey).
RESULTS
Respondents
Of the 510 distributed surveys, a total of 122 (24%)
were returned by surgical oncologists, which represented
95% of all registered specialized breast surgeons. The
median number of years working as an oncological surgeon
was 13, ranging from 1 to 35 years. Twenty-six (21%)
respondents had up to 5 years’ experience as a surgeon, 24
(20%) had 5–10 years’ experience, 23 (19%) had
10–15 years’ experience, 18 (15%) had 25–20 years’
experience, 7 (6%) had 20–25 years’ experience, 10 (9%)
had 25–30 years’ experience, and one respondent had over
30 years of experience.
Sentinel Node Procedure
During the SLN procedure, 87% (106/122) reported
using both the lymphoscintigraphy and Patent Blue tech-
nique, while 13% (16/122) used the lymphoscintigraphy
technique only. None of the respondents used Patent Blue
only. When asked to estimate how many times the sentinel
node could not be visualized, 35% (43/122)
answered\1%, 39% (48/122) answered between 1 and
2%, 25% (30/122) answered between 2 and 5%, and one
respondent estimated the sentinel node could not be
visualized in more than 5% of cases. The estimated
prevalence of non-vSLNs was not significantly different
between surgeons who only used the lymphoscintigraphy
technique versus those who combined lymphoscintigraphy
with Patent Blue. When asked to estimate the prevalence of
any lymph node metastases in patients with a non-vSLN,
26% (30/117) of respondents estimated it to be\25%, 38%
(44/117) estimated it to be between 25 and 30%, and 37%
(43/117) estimated it to be more than 30%.
Axillary Treatment
Table 1 shows additional responses to the survey. What
stands out is that in all scenarios of an unsuccessful SLN
harvesting, neither with lymphoscintigraphy nor with
Patent Blue, axillary treatment has changed substantially
after publication of the Z0011 trial. Prior to the Z0011 trial,
the majority (approximately 80%) of respondents answered
they would always perform an ALND in case of a non-
vSLN. After publication of the Z0011 trial, this number has
dropped to approximately 15%. At present, the majority of
respondents (60%) declared they only perform an ALND
when they expect an increased risk of nodal involvement
based on various clinicopathological characteristics, as
illustrated in Fig. 1. In the past, only 10–15% of breast
surgeons based their decision on such clinical factors.
Moreover, 23 (19%) respondents answered they would opt
for an alternative axillary treatment instead of a complete
ALND in case of a non-vSLN; two respondents indicated
they would not perform an ALND at all, 11 respondents
indicated they would perform an incomplete ALND, seven
respondents would opt for 4-node sampling, two respon-
dents would redo the SLN procedure, and one respondent
would consult a multidisciplinary team for further treat-
ment recommendations.
Subanalyses differentiating between years of experience
as a surgeon (less than 10 vs. 10 or more years) showed no
significant differences in the methodology of the SLN
procedure or in preferences for axillary treatment in case of
a non-vSLN, prior to or after the Z0011 trial. What did
differ was that the experienced surgeons (10 or more years
of experience) more often expected the ALND to be
redundant in the future, and they thought that the guideline
should be revised for patients with a non-vSLN.
Additional Comments
At the end of the survey, respondents could add sup-
plementary comments and opinions. The comment most
frequently made was that an ALND should not be per-
formed on patients with a low risk of axillary disease,
depending on tumor characteristics and the age of the
patient, as shown in Fig. 1. Some respondents
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recommended administering adjuvant axillary radiotherapy
or performing a partial, instead of a complete, ALND,
especially if there is an indication for adjuvant systemic
therapy.
Many respondents indicated that the upcoming revised
Dutch guideline regarding axillary treatment in case of a
non-vSLN should not only differentiate between patients
with low risk of axillary disease versus patients with high
TABLE 1 Responses on questions asked in the survey regarding routines of axillary treatment in case of a non-vSLN, prior to versus after the
Z0011 trial
Questions
Prior to the Z0011 trial Currently
1 (A ? B) N = 120 N = 122
What do/did you do when the sentinel node could not be visualized after
lymphoscintigraphy and the use of a gamma probe?
I will perform an immediate axillary lymph node dissection (ALND) 35 (30.3%) 1 (0.8%)
I will refrain from further axillary treatment 0 5 (4.1%)
I will attempt to find the sentinel node by means of Patent Blue (see question 2) 79 (64.8%) 92 (75.4%)
Whether I will perform an immediate ALND depends on patient and tumor
characteristics, such as …
6 (4.9%) 22 (18%)
Never happened 0 2 (16%)
2 (A ? B) N = 115 N = 118
If in the previous question you chose to attempt to find the sentinel node by means of
Patent Blue (option C), what do/did you do in case the sentinel node could not be
visualized during this procedure?
I will perform an immediate ALND 94 (81.7%) 17 (14.4%)
I will refrain from further axillary treatment 4 (3.5%) 27 (22.9%)
Whether I will perform an immediate ALND depends on patient and tumor
characteristics, such as …
13 (11.3%) 71 (60.2%)
Never happened 4 (3.5%) 3 (2.5%)
3 (A ? B) N = 118 N = 119
What do/did you do in case the sentinel node could be visualized during the
lymphoscintigraphy, but not during the operation, after using Patent Blue?
I will perform an immediate ALND 94 (79.7%) 19 (16%)
I will refrain from further axillary treatment 1 (0.8) 25 (21%)
Whether I will perform an immediate ALND depends on patient and tumor
characteristics, such as …
1 (14.4%) 67 (56.3%)
Never happened 6 (51%) 8 (6.7%)
No Yes
4
I still execute the Dutch guideline of 2012 regarding the axillary work-up and
treatment (n = 117)
63 (54%) 54 (46%)
Currently, the guideline regarding axillary work-up is clear-cut (n = 120) 85 (71%) 35 (29%)
I always perform a sentinel node procedure (n = 121) 11 (9%) 110 (91%)
Sometimes, in case of a negative axillary ultrasound, I omit further axillary
diagnostics, including the sentinel node procedure (n = 120)
114 (95%) 6 (5%)
In addition to the axillary ultrasound, I apply additional imaging techniques to
evaluate axillary nodal status, such as PET, PET/CT, MRI, etc. (n = 119)
63 (53%) 56 (47)
The confusion on the axillary work-up has increased (n = 120) 34 (28%) 86 (72%)
In my opinion, the sentinel node procedure will be obsolete and will disappear within
the next few years (n = 120)
80 (67%) 40 (33%)
Surgical treatment of the axilla is, or will be, redundant (n = 119) 94 (79%) 25 (21%)
The guideline should be revised regarding further
axillary treatment in case of a non-visualized sentinel node. If so, which aspect?
(n = 113)
24 (21%) 89 (79%)
non-vSLN non-visualized sentinel lymph node, PET positron emission tomography, CT computed tomography, MRI magnetic resonance imaging
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risk but should also be more specific on the best axillary
treatment options, such as partial ALND or axillary
radiotherapy.
DISCUSSION
The present study shows the results of a nationwide
survey, which was distributed among certified oncological
(breast) surgeons in The Netherlands, regarding routine
practice during the SLN procedure and the axillary treat-
ment in case of a non-visualized and non-retrieved SLN.
The data show that respondents are currently more reserved
in performing a complete ALND in case of a non-vSLN
compared with the period prior to publication of the Z0011
trial. Moreover, the indication to perform an ALND
nowadays mostly depends on clinicopathological factors.
The Z0011 trial caused a paradigm shift in the axillary
treatment of clinically node-negative but SLN-positive
patients. This trial compared the effects of ALND after
SLNB versus SLNB alone on (disease-free) survival and
concluded that omitting the ALND in some of these
patients did not negatively affect (disease-free) survival.
Patients in whom the ALND could be omitted can be
selected by using the so-called ‘Z0011 criteria’: (i) invasive
breast cancer; (ii) clinical tumor size B5 cm (T1–2); (iii)
no palpable lymphadenopathy; (iv) one or two positive
sentinel nodes; and (v) treated with lumpectomy.1 In
addition, the European Organization for Research and
Treatment of Cancer (EORTC) AMAROS (After Mapping
of the Axilla: Radiotherapy or Surgery) trial showed that in
SLN positive patients with T1–2 invasive breast cancer
without lymphadenopathy, administering axillary radio-
therapy was not inferior to an ALND in providing
locoregional disease control.2 Next to these two studies,
numerous other studies have shown that the ALND is no
longer absolutely necessary in every breast cancer patient
and, consequently, various prediction models and scoring
systems have been developed to select patients in whom
the ALND could be omitted.11–15 Although these studies
provide a promising perspective for breast cancer patients,
as the ALND can cause significant morbidity, they only
included patients with a positive SLN, thereby disregarding
clinically node-negative patients in whom the SLN could
not be retrieved.
This scarcity of studies has also caused some ambiguity
between international guidelines in axillary treatment rec-
ommendations in case of a non-vSLN, provided that
treatment options are mentioned at all. The current Dutch
NABON guideline states that in case of a non-vSLN, an
ALND should be performed for locoregional control.6 The
recommendations in the American Society of Clinical
Oncology (ASCO) guideline, as well as the Australian
guideline, are identical to the Dutch guideline. The
National Comprehensive Cancer Network (NCCN) guide-
line also concurs; however, a footnote has been added
which states that in case of clinically negative axillary
lymph nodes and treatment with mastectomy and radiation
therapy, an extended radiation field to the axilla may also
be sufficient.8,9,16 Currently, only the NCCN guideline has
implemented the Z0011 criteria in its recommendations.1,9
Both the European Society for Medical Oncology
(ESMO) and British National Institute for Health and Care
Excellence (NICE) guidelines do not mention the possi-
bility of a non-vSLN, or its implications for treatment.10,17
Therefore, the question remains as to what the optimal
axillary treatment is in case of a non-vSLN. Studies have
shown that older age, a high body weight, larger tumor size,
and a high number of positive lymph nodes and
macrometastases can decrease the success rate of the SLN






















making on whether or not to
perform an immediate ALND in
case of a non-vSLN, with
percentage of respondents
mentioning these factors. ALND
axillary lymph node dissection,
non-vSLN non-visualized
sentinel lymph node
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axilla remains important, especially in case of a non-vSLN,
to locate any suspicious nodes that are not identified by
Patent Blue or lymphoscintigraphy. Although we did not
explicitly ask this in our survey, in The Netherlands this is
common practice. In a previous study, which has yet to be
published, we examined potential differences in patient
characteristics and prognosis between patients with a non-
vSLN versus those in whom SLN was successfully har-
vested (vSLN). This study showed that older patients,
patients diagnosed prior to 2006, and patients with a large
tumor were more likely to have an unsuccessful SLN pro-
cedure. Moreover, non-vSLN patients had a significantly
worse survival compared with patients in whom the SLN
could be retrieved. However, performing an ALND in non-
vSLN patients did not significantly improve prognosis. This
supports the tendency of many surgeons to not (uncondi-
tionally) perform a complete ALND in case of a non-vSLN.
The present survey is the first to assess current clinical
practice among Dutch oncological surgeons in case of a
non-vSLN. Although this survey is limited and not vali-
dated yet, its high response by Dutch breast surgeons
makes it quite representative. The results provide relevant
and important insights into the diversity in axillary treat-
ment given by Dutch breast surgeons in case of a non-
vSLN. Moreover, this survey has shown that decisions on
whether or not to perform an ALND in case of a non-vSLN
has changed after publication of the Z0011 trial, irrespec-
tive of the surgeon’s years of experience. A more extensive
and validated international survey is warranted for more
scientifically-based conclusions on the diversity of given
axillary treatments.
CONCLUSIONS
The results of this survey show that Dutch breast sur-
geons are more reserved to perform an ALND in patients
with a non-visualized sentinel node, especially after pub-
lication of the Z0011 trial. According to the answers given
in this survey, the decision on whether or not to perform an
ALND nowadays mostly depends on multiple clinico-
pathological characteristics. More research is warranted to
determine the optimal axillary treatment in patients with
non-vSLN to be able to provide evidence-based recom-
mendations in international guidelines.
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